Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Antibodies

Anti-Amyloid beta (aa 4-10) [WO2]

Product Sizes
0.1 mg
£799.00
ORB348874-0.1MG
About this Product
SKU:
ORB348874
Application:
ELISA, IHC-Paraffin, Western Blot
Buffer:
PBS with 0.02% Proclin 300.
translate.label.attr.clone:
WO2
Clonality:
Monoclonal
Conjugate:
Unconjugated
Concentration:
1 mg/ml
Host:
Mouse
Immunogen:
Synthetic peptides; corresponding to amino acids 1-42 of human beta amyloid; conjugated to KLH.
Isotype:
IgG2a
Purity:
Purified
Reactivities:
Human
Shipping Conditions:
Blue Ice
Storage Conditions:
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Supplier:
Biorbyt
Type:
Antibodies: Monoclonal Antibody
Comparison of recombinant WO2 anti-Amyloid beta (orb348874) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed; by this method; comparative purity. Subsequently; the specificity of the antibodies was tested in assays detecting immobilised peptides (see B); in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity; however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.
Comparison of recombinant WO2 anti-Amyloid beta (orb348874) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed; by this method; comparative purity. Subsequently; the specificity of the antibodies was tested in assays detecting immobilised peptides (see B); in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity; however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.
Comparison of recombinant WO2 anti-Amyloid beta (orb348874) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed; by this method; comparative purity. Subsequently; the specificity of the antibodies was tested in assays detecting immobilised peptides (see B); in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity; however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.